Traditional Treatment Course for Moderate-to-Severe RA Disease

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting 1% of the population. If left untreated or undertreated, patients with RA can suffer from joint destruction as well as a wide array of debilitating extra-articular, systemic effects. This web-based interactive enduring activity will provide participants with the opportunity to assess new data and recent treatment recommendation updates regarding the use of disease-modifying anti-rheumatic drugs (DMARDs) to optimize treatment of those with moderate-to-severe RA. Participants will also learn to select appropriate, individualized treatment and initial and escalation therapies for patients with RA, enabling healthcare providers to better identify those in whom an IL-6 inhibitor or other non-TNFi therapy may be an appropriate therapy.

COURSE GOAL

The goal of this activity is to provide rheumatologists and other healthcare professionals with valuable clinical insights that assess new and emerging therapies for patients with RA, including IL-6 inhibitors, and explore the effective use of these newer therapies in clinical practice.

TARGET AUDIENCE

This activity is intended for rheumatologists and other healthcare providers (physicians, nurse practitioners, and physicians’ assistants) who treat patients with RA.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Assess new data and recent treatment recommendation updates regarding the use of DMARDs for moderate to severe RA.
  2. Select appropriate, individualized initial and escalation therapies for patients with RA.

FACULTY

Roy Fleischmann, MD, MACR (Chair)
Clinical Professor of Medicine
Department of Internal Medicine
University of Texas Southwestern Medical Center
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Tsutomu Takeuchi, MD, PhD
General Director, Keio University Hospital
Professor of Medicine, Division of Rheumatology
Department of Internal Medicine
Keio University School of Medicine
Tokyo, Japan

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Roy Fleischmann, MD, MACR

Consultant/Advisor: Amgen Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Janssen Global Services, LLC; Pfizer Inc.; Sanofi-Regeneron; UCB Inc.

Grant/Research Support: Amgen Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Janssen Global Services, LLC; Pfizer Inc.; Sanofi-Regeneron; UCB, Inc.

Speakers’ Bureau: Pfizer Inc.

Tsutomu Takeuchi, MD, PhD

Consultant/Advisor: AbbVie Inc.; Asahi Kasei Corporation; Astellas Pharma Inc.; AstraZeneca; Bristol-Myers Squibb Company; Daiichi Sankyo Company, Limited; Eli Lilly and Company; Janssen Global Services, LLC; Merck KGaA; Mitsubishi Tanabe Pharma Corporation; Pfizer Inc.; Nippon Kayaku Co.,Ltd.; Takeda Pharmaceutical Company Limited

Grant/Research Support: AbbVie Inc.; Asahi Kasei Corporation; Astellas Pharma Inc.; AYUMI Pharmaceutical Corporation; Bristol-Myers Squibb Company; Chugai Pharmaceutical Co., Ltd; Daiichi Sankyo Company, Limited; Eisai Co., Ltd.; Taisho Pharmaceuticals Co., Ltd.; Takeda Pharmaceutical Company Limited

Speakers’ Bureau: AbbVie Inc.; Astellas Pharma Inc.; Bristol-Myers Squibb Company; Chugai Pharmaceutical Co., Ltd; Daiichi Sankyo Company, Limited; Eisai Co., Ltd.; Janssen Global Services, LLC; Mitsubishi Tanabe Pharma Corporation; Nippon Kayaku Co.,Ltd.; Pfizer Inc.

Non-faculty: Christina M. Ohnsman, MD; Jessica Marshall, PharmD; Lou Settembrino; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

Supported by an independent educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.

Provider Information

Co-sponsored by the Elsevier Office of Continuing Medical Education and ASiM.

 

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Genzyme, a Sanofi Company and Regeneron Pharmaceuticals. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician
Course opens: 
04/28/2017
Course expires: 
04/27/2018
Rating: 
0

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician

Accreditation Period

Course opens: 
04/28/2017
Course expires: 
04/27/2018
Please login or register to take this course.